Erin Newburn, MS, PhD
Director, Field Application Scientist
Enabling Composite Biomarker Discovery for Precision Cancer Therapy with an Enhanced Exome and Transcriptome Platform
- In this presentation, we’ll provide an overview of the ImmunoID NeXT Platform and how it can be used to explore critical immunotherapy-related resistance mechanisms and novel composite biomarkers of response utilizing analytics including human leukocyte antigen (HLA) typing and HLA loss of heterozygosity (LOH), neoantigen prediction and load, immune repertoire characterization, oncoviral detection, as well as the evaluation of tumor mutational burden (TMB) and microsatellite instability (MSI) status.
- In addition, we’ll review a recent case study from a cohort of metastatic melanoma patients who were treated with immune checkpoint blockade, where we integrated several different molecular features from the ImmunoID NeXT platform to help better define the responder and non-responder patients.